Home
Conditions
Borderline Resectable Pancreatic Ductal Adenocarcinoma

Clinical trial condition

Borderline Resectable Pancreatic Ductal Adenocarcinoma

Explore clinical trials studying Borderline Resectable Pancreatic Ductal Adenocarcinoma. Study availability and eligibility vary by location and protocol.

10 public trials 6 recruiting studies

Refine in advanced search Browse all conditions

Borderline Resectable Pancreatic Ductal Adenocarcinoma trial results

Recruiting

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

NCT06423326

Conditions: Borderline Resectable Pancreatic Ductal Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, +10 more
Locations: Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States

View Trial Details

Recruiting

NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial

NCT06821997

Conditions: Borderline Resectable Pancreatic Ductal Adenocarcinoma
Locations: Roswell Park Cancer Institute Buffalo, New York, United States

View Trial Details

Recruiting

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

NCT04005690

Conditions: Borderline Resectable Pancreatic Ductal Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, +13 more
Locations: OHSU Knight Cancer Institute Portland, Oregon, United States

View Trial Details

Recruiting

Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment

NCT06574620

Conditions: Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, +1 more
Locations: BC Cancer Vancouver, British Columbia, Canada

View Trial Details

Recruiting

PULSAR in Systemic Therapy for Pancreatic Cancer

NCT07269626

Conditions: Borderline Resectable Pancreatic Ductal Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, +8 more
Locations: Samsung Medical Center Seoul, Select Province/State, South Korea

View Trial Details

Recruiting

Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy

NCT06595160

Conditions: Borderline Resectable Pancreatic Ductal Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, +8 more
Locations: Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States

View Trial Details

Not Yet Recruiting

DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer

NCT07705919

Conditions: Borderline Resectable Pancreatic Ductal Adenocarcinoma
Locations: Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States

View Trial Details

Not Yet Recruiting

Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer

NCT07645651

Conditions: Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
Locations: Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Not Yet Recruiting

Personalize (Signature Driven) Neoadjuvant Chemotherapy Trial for Patients With Resectable Borderline Pancreatic Ductal Adenocarcinoma.

NCT07616362

Conditions: Borderline Resectable Pancreatic Ductal Adenocarcinoma
Locations: Hôpital Beaujon Clichy, France

Institut Paoli Calmettes Marseille, France

Hôpital Lyon Sud Pierre-Bénite, France

Hopital Nord Chu Saint Etienne Saint-Priest-en-Jarez, France

View Trial Details

Not Yet Recruiting

AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer

NCT07619313

Conditions: Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma, Carcinoma, +18 more
Locations: UCLA / Jonsson Comprehensive Cancer Center Los Angeles, California, United States

View Trial Details

Borderline Resectable Pancreatic Ductal Adenocarcinoma

Borderline Resectable Pancreatic Ductal Adenocarcinoma trial results

Related conditions